HEALTH

Identigene: Resolving paternity questions a growing New Year’s resolution

BY Michael Johnsen

SALT LAKE CITY — According to a survey released by Identigene last week, more than half of adults with paternity questions have resolved to address their question in 2012. Men with paternity questions are twice as likely (51%) than women (25%) to address paternity in 2012.

Overall, as many as 11% of adults have reported they have personally been in a situation where a paternity test was appropriate; and nearly 1-in-5 (18%) said that they or a close friend or family member have questioned paternity.

The research helped to confirm a seasonal sales trend identified by Identigene in its sales of Identigene DNA paternity test — each year the company experiences a spike in first-quarter sales, which the company attributes, in part, to New Year’s resolutions.

“The new year definitely seems to trigger many adults with paternity questions to take steps to address their question,” stated Steven Smith, executive director for Identigene.

Although the specific reasoning for paternity testing varies from person to person, the benefits of confirming paternity are multifaceted and far reaching. In the survey, 3-in-4 adults (77%) said they believe it’s important for a child to know his or her biological father.

From emotional and health benefits to financial welfare, paternity answers can have many important and positive impacts for children. “Knowledge is empowering,” Smith said. “It’s important for children and families to know the truth about paternity, as it can impact a child’s health, as well as their emotional health and well-being for years to come.” 

 


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

Perrigo announces summertime availability of desloratadine in Rx and OTC

BY Michael Johnsen

ALLEGAN, Mich. — Perrigo last week announced that it has received final Food and Drug Administration approval for its generic prescription allergy remedy desloratadine 5 mg, the generic equivalent to Schering-Plough’s Clarinex.

Under the terms of a patent-infringement suit settlement, Perrigo can commercially launch its generic desloratadine product July 1. The new product launch may be a prescription or over-the-counter product, depending on its status at the time of launch, Perrigo stated.

Clarinex sales were approximately $185 million, according to Perrigo, citing Wolters Kluwer data.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

Nutramax renews contract Cosamin spokesman Jim Palmer

BY Michael Johnsen

EDGEWOOD, Md. — Nutramax Labs on Tuesday announced the continuation of its partnership with Major League Baseball’s Hall of Fame pitcher Jim Palmer in promoting Cosamin joint health supplements in national and regional marketing campaigns and events.

“We are pleased to enter into our 12th year of partnership with Jim Palmer,” stated Troy Henderson, VP corporate operations and professional services. "Palmer is an excellent [spokesman] for Cosamin joint health supplements because Cosamin is not just for athletes, but for anyone who is active.”

“Twelve years ago, my orthopedic doctor recommended Cosamin for my joint pain,” Palmer said. “I’ve been using it ever since — and at 65, I’m still very active and doing the things I love most since retiring from Major League Baseball in 1985.”

 


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES